Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura A Solt

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Future Medicinal Chemistry|April 30, 2011
The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasisLaura A Solt, Douglas J Kojetin, Thomas P Burris
Current Opinion in Lipidology|May 14, 2010
Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeuticsLaura A Solt, Patrick R Griffin, Thomas P Burris
Immunometabolism|December 13, 2021
A Compass to Guide Insights into T<sub>H</sub>17 Cellular Metabolism and AutoimmunityAdrianna N Wilson, Sarah A Mosure, Laura A Solt
Plos One|October 3, 2012
LXR-mediated inhibition of CD4+ T helper cellsLaura A Solt, Theodore M Kamenecka, Thomas P Burris
Biochemical and Biophysical Research Communications|May 23, 2020
Pharmacological modulation and genetic deletion of REV-ERBα and REV-ERBβ regulates dendritic cell developmentMohammed Amir, Sean Campbell, Theodore M Kamenecka, et al.
Plos One|April 18, 2012
Regulation of p53 stability and apoptosis by a ROR agonistYongjun Wang, Laura A Solt, Douglas J Kojetin, et al.
Biochemical Pharmacology|January 23, 2018
REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009Ariadna Amador, Theodore M Kamenecka, Laura A Solt, et al.
The Journal of Biological Chemistry|January 25, 2007
Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbetaLaura A Solt, Lisa A Madge, Jordan S Orange, et al.
Biochemical and Biophysical Research Communications|March 25, 2015
Suppression of atherosclerosis by synthetic REV-ERB agonistSadichha Sitaula, Cyrielle Billon, Theodore M Kamenecka, et al.
Endocrinology|January 7, 2015
ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetesLaura A Solt, Subhashis Banerjee, Sean Campbell, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Future Medicinal Chemistry|April 30, 2011
The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasisLaura A Solt, Douglas J Kojetin, Thomas P Burris
Current Opinion in Lipidology|May 14, 2010
Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeuticsLaura A Solt, Patrick R Griffin, Thomas P Burris
Immunometabolism|December 13, 2021
A Compass to Guide Insights into T<sub>H</sub>17 Cellular Metabolism and AutoimmunityAdrianna N Wilson, Sarah A Mosure, Laura A Solt
Plos One|October 3, 2012
LXR-mediated inhibition of CD4+ T helper cellsLaura A Solt, Theodore M Kamenecka, Thomas P Burris
Biochemical and Biophysical Research Communications|May 23, 2020
Pharmacological modulation and genetic deletion of REV-ERBα and REV-ERBβ regulates dendritic cell developmentMohammed Amir, Sean Campbell, Theodore M Kamenecka, et al.
Plos One|April 18, 2012
Regulation of p53 stability and apoptosis by a ROR agonistYongjun Wang, Laura A Solt, Douglas J Kojetin, et al.
Biochemical Pharmacology|January 23, 2018
REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009Ariadna Amador, Theodore M Kamenecka, Laura A Solt, et al.
The Journal of Biological Chemistry|January 25, 2007
Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbetaLaura A Solt, Lisa A Madge, Jordan S Orange, et al.
Biochemical and Biophysical Research Communications|March 25, 2015
Suppression of atherosclerosis by synthetic REV-ERB agonistSadichha Sitaula, Cyrielle Billon, Theodore M Kamenecka, et al.
Endocrinology|January 7, 2015
ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetesLaura A Solt, Subhashis Banerjee, Sean Campbell, et al.
Pageof 7